Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?

about

Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?

Item

http://www.wikidata.org/entity/Q54242357

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Magnetic resonance examination ...... riple-negative breast cancers?

@en

Magnetic resonance examination ...... riple-negative breast cancers?

@nl

type

Item

label

Magnetic resonance examination ...... riple-negative breast cancers?

@en

Magnetic resonance examination ...... riple-negative breast cancers?

@nl

prefLabel

Magnetic resonance examination ...... riple-negative breast cancers?

@en

Magnetic resonance examination ...... riple-negative breast cancers?

@nl

P1476

Magnetic resonance examination ...... riple-negative breast cancers?

@en

P2093

Koichiro Tsugawa

http://www.w3.org/2001/XMLSchema#string

Satoko Okamoto

http://www.w3.org/2001/XMLSchema#string

Takayuki Yamada

http://www.w3.org/2001/XMLSchema#string

Yasuo Nakajima

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Kojima

http://www.w3.org/2001/XMLSchema#string

Yoshihide Kanemaki

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.

Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

P2888

s12282-015-0642-7

P304

789-796

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-015-0642-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26437647

http://www.w3.org/2001/XMLSchema#string